查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840604

患者血液管理市場按產品類型、治療類型、應用和最終用戶分類 - 全球預測 2025-2032

Patient Blood Management Market by Product Type, Therapy Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，患者血液管理市場規模將達到 322.2 億美元，複合年成長率為 8.23%。

主要市場統計數據
基準年 2024 171億美元
預計年份：2025年 185億美元
預測年份：2032年 322.2億美元
複合年成長率 (%) 8.23%

整合實施病人血液管理，明確臨床優先事項、保障供應彈性以及運用技術手段，以推動圍手術全期安全和機構策略。

病患血液管理正發展成為圍手術全期照護、輸血醫學、供應鏈管理和以價值為導向的臨床結果等多個領域交叉的必要環節。該領域優先考慮最大限度地減少異體血液暴露、最佳化止血以及根據患者獨特的風險狀況量身定做治療性介入。隨著醫院和專科中心應對日益複雜的手術流程以及對安全性和成本的日益嚴格審查，患者血液管理實踐在臨床管治和品質改進議程中變得越來越重要。

臨床醫生、管理人員和供應鏈負責人現在從多個角度看待患者血液管理 (PBM)：臨床療效、手術效率和應對血液供應中斷的能力。床邊凝血監測和自體血液技術的進步使得術中決策更加精準，而止血劑、密封劑和一次性系統的創新則有助於建立更安全的手術通道。這些技術變革，加上不斷完善的臨床通訊協定（強調術前最佳化和術後保護），使得 PBM 成為臨床和組織層面的雙重優先事項。

此外，以病人為中心的照護模式正在重新思考治療方法方案的溝通和實施方式。圍繞著輸血閾值、自體血液回收和抗纖溶治療等方案的共用決策，以及圍手術全期最佳化通訊協定的整合，凸顯了醫院和專科中心更廣泛的文化轉變。在此背景下，患者血液管理成為提升臨床卓越、運作韌性和改善患者預後的有效途徑。

深入分析臨床、技術和營運方面的變革，這些變革正在重新定義醫療保健機構中的患者血液管理實踐和採購重點。

血液管理格局正受到多種因素的共同影響而再形成，這些因素正在重新定義臨床管道和籌資策略。自體輸血系統和血液分離設備的成熟，使得自體血液的再利用更加安全，並減少了對外部血液供應的依賴；而新一代凝血監測系統和照護現場技術則支持更快速、更循證的術中干涉。這些進步提高了手術全期決策的精細化程度，並增強了即時數據在指導輸血實踐中的作用。

同時，止血劑、密封系統和局部用藥的研發和廣泛應用，徹底改變了各專科手術出血的管理方式。改良的配方和給藥機制縮短了手術時間，減少了輸血需求，並與抗纖溶藥物和擴容劑聯合使用，支持更保守的輸血策略。這些臨床進展與按服務付費和基於價值的採購模式的營運趨勢相契合，獎勵醫院展示以結果為導向的藥品福利管理（PBM）工具應用。

最後，醫療模式向分散化轉型以及門診手術中心的興起，迫使製造商和供應商調整產品設計和服務模式，以適應多樣化的醫療環境。隨著醫療模式逐漸擺脫傳統的住院模式，旨在提高速度和便攜性的照護現場設備以及一次性解決方案變得日益重要。因此，相關人員必須權衡技術創新與訓練、互通性和長期臨床證據之間的關係，才能充分發揮這項變革性轉變所帶來的益處。

深入分析近期關稅措施將如何影響患者血液管理生態系統的供應鏈韌性、籌資策略、製造本地化和臨床應用模式。

關稅政策的變化可能會對醫療設備和耗材供應鏈產生連鎖反應，進而改變醫院、專科中心和經銷商的採購成本。關稅可能會增加關鍵零件和成品的進口成本，進而可能提高醫療服務提供者採購自體輸液系統、凝血監測儀、止血劑和耗材的成本。這種變化將迫使供應鏈領導者重新評估其籌資策略，評估總體擁有成本，並優先考慮擁有多元化製造地和本地生產能力的供應商。

除了短期價格影響外，主導調整也將影響供應商的長期策略。製造商可能會加快關鍵產品的在地化生產，投資區域製造地，或調整產品系列以減少對脆弱供應鏈的依賴。雖然這些舉措可能在長期內增強韌性，但短期內可能需要資本支出，並影響定價權。對於供應商而言，這將促使他們更加重視採購的彈性。多供應商協議、庫存最佳化以及包含靈活條款的長期採購協議將是緩解市場波動的重要工具。

臨床上，除非醫療機構能夠明確證明某些技術與改善療效或提高營運效率之間存在關聯，否則較高的設備和耗材成本可能會影響這些技術的普及。因此，用確鑿的證據證明其臨床和經濟價值對於維持技術的普及至關重要。最後，新關稅制度引入的法律規範和海關合規複雜性可能會增加行政負擔，要求醫療機構投資於合規能力建設，並與供應商更緊密地合作，以簡化跨境物流並確保持續獲得​​關鍵的藥品福利管理（PBM）產品。

全面的細分洞察揭示了產品類別、治療方法、臨床應用和醫療保健環境如何相互作用，從而影響產品採納管道和商業化策略。

深入的市場區隔揭示了臨床需求、技術契合度和購買行為之間的交集，從而能夠針對產品、療法、應用和終端用戶等多個維度製定精準策略。產品類型包括抗纖溶藥物、自體輸血系統、血液成分分離系統、血液管理拋棄式、凝血監測系統、止血劑和密封劑以及血液容積擴充劑。血液管理拋棄式主要包括細胞清洗試劑套件、收集容器和過濾裝置；凝血監測細分市場分為實驗室分析儀和照護現場設備；止血劑和密封劑細分市場分為密封劑系統和局部止血劑。每個產品類型都呈現出獨特的市場推廣路徑，其促進因素包括臨床證據、易用性、耗材經濟性和與手術全期流程的整合。

治療方法類型涵蓋異體輸血、自體輸血、細胞回收、止血管理及手術全期手術期血液保護。止血管理領域進一步細分為抗纖溶治療和局部止血治療，而手術全期血液保護則包括術中技術、術後護理和術前最佳化。以治療為中心的細分揭示了臨床方案和多學科團隊如何在哪些方面最有效地減少輸血暴露並改善預後，其中手術全期最佳化通常是連接術前評估和術中技術應用的關鍵環節。

心血管外科手術的臨床複雜程度因主動脈手術、冠狀動脈繞道手術繞道手術和瓣膜置換術而異，而腫瘤科手術則根據化療和放療的具體情況而有所不同。擇期手術計畫通常著重於術前最佳化和術中止血管理，創傷照護著重於快速取得照護現場凝血數據和血液成分分離，而腫瘤科手術則需要協調一致的策略來管理複雜治療方法中的出血風險。

從終端使用者的角度來看，這些設備的應用模式涵蓋了門診手術中心、診所、醫院和專科中心。專科中心可進一步細分為癌症治療中心、心臟治療中心和創傷中心。每種醫療環境都有不同的需求，包括設備佔地面積、訓練強度、耗材物流以及報銷敏感度。門診環境優先考慮緊湊易用且耗材精簡的設備，而三級醫院和專科中心則需要能夠與加護治療工作流程整合並可擴展以支援大量高風險病例的系統。了解這些細分領域的動態對於產品定位、證據收集以及製定能夠引起臨床醫生和採購相關人員共鳴的商業策略至關重要。

對美洲、中東和非洲以及亞太地區的醫療保健結構、報銷模式和法規環境如何推動差異化患者血液管理的普及進行策略性檢驗。

區域動態影響臨床實務模式、採購偏好和監管策略，導致不同地區的醫療服務採納路徑各異。在美洲，醫療保健系統涵蓋了大型綜合醫院網路和數量眾多的門診手術中心，這不僅催生了對高階整合系統的需求，也催生了對攜帶式照護現場方案的需求。此外，報銷模式和私人支付方的影響力也在加速循證藥品福利管理（PBM）干預措施的推廣應用，因為成本效益數據可以直接指導採購決策。

歐洲、中東和非洲地區監管和報銷環境的差異導致了不同的技術採納曲線。西方醫療體係由於其集中採購和對臨床指南的重視，往往傾向於採用有可靠臨床數據和長期療效研究支持的技術。而該地區的新興市場則以夥伴關係關係為驅動，這些合作關係能夠降低成本、提供模組化解決方案、進行本地培訓並確保供應的穩定性。監管協調工作和區域採購舉措可能會促進或阻礙市場准入，具體取決於合規性以及認證管道。

在亞太地區，手術量的快速成長和醫院基礎設施的持續投入，為加速應用病患血液管理（PBM）技術創造了機會。不同的醫療融資模式和醫療服務提供者的能力，正在塑造對可擴展設備、高效拋棄式和經濟實惠的止血解決方案的需求。在亞太地區的許多市場，在地化生產和與國內經銷商的策略聯盟正在最佳化成本結構，並促進技術的快速應用，尤其是在不斷拓展外科和腫瘤治療的三級醫療中心和專科中心。總而言之，成功的區域策略需要協調當地的監管要求、醫療資金籌措模式和醫療服務提供者的診療模式。

權威概述了全球血液管理領域的製造商、利基創新者和區域供應商如何透過臨床證據、供應彈性和夥伴關係主導的商業化來競爭。

競爭格局由多元化的全球製造商、專業設備創新者和靈活的區域供應商組成，他們都致力於以臨床證據、服務交付和供應鏈韌性為核心的策略。成熟的設備製造商利用其廣泛的產品系列，提供整合解決方案，例如自動化輸血系統、凝血監測平台和拋棄式；而規模較小的創新者則通常提供針對特定臨床痛點的技術，例如先進的密封劑、一次性過濾系統和快速照護現場分析儀。

企業採取的策略行動包括投資臨床證據的產生、拓展分銷管道以及與臨床中心合作，以實驗方式引入新技術。與實際進行證據收集工作的醫院和專科中心合作，能夠增強企業的價值提案，並有助於將相關成果納入指南。同時，供應鏈整合和生產多元化是關鍵的差異化因素，企業正在探索區域生產基地和多源採購模式，以應對貿易中斷和關稅變化的影響。

併購和授權授權持續影響企業的能力組合，使企業能夠透過耗材和服務來補充其設備產品，從而確保持續的收入來源。同時，企業正著力於培訓、遠距服務和數位化工具，以提升產品應用率和長期客戶維繫。對於買家和合作夥伴而言，關鍵在於檢視供應商在臨床效用、整體擁有成本、實證醫學證據、支持和供應連續性方面的承諾是否一致。

為實現持久患者血液管理的成功，建議高階主管和臨床領導者採取以下行動，以協調證據產生、供應多樣化、定價靈活性和患者特定採用策略。

產業領導者應優先考慮協作方式，將臨床證據的產生與適應性供應鏈策略和商業模式結合，以適應個人化的醫療環境。投資於嚴謹的臨床研究，以證明其能夠改善治療效果和提高手術效率，有助於證明相關設備和治療方法的合理性，即使在預算緊張的情況下也是如此。同樣重要的是，彈性價格設定和合約選項應反映總體擁有成本，使醫院能夠以有限的前期投資試用新技術。

在營運方面，企業和醫療服務提供者網路應加快推動生產和分銷管道多元化，以降低海關和物流風險。在地化生產或與區域製造商建立策略聯盟可以減少跨境中斷的風險，並在競爭性採購過程中創造成本優勢。同時，建立全面的培訓計畫和遠端支援體係可以確保新技術得到安全有效的應用，從而增強臨床醫生的信心並促進其永續使用。

最後，產品開發與終端用戶實際需求的契合至關重要。專為門診和診所環境設計的易用型設備和耗材將擴大目標市場，而可擴展至三級醫院的模組化系統則能滿足專科中心的需求。臨床團隊、採購部門和供應商客戶經理之間的跨職能協作將加速藥品福利管理（PBM）實踐融入標準診療流程，並確保長期價值的實現。

我們透明嚴謹的調查方法結合了專家訪談、臨床指南整合、細分市場映射和檢驗研討會，以支持我們的策略洞察，而無需依賴專有的市場量化。

調查方法整合了多個資料流和專家檢驗，以確保研究結果的可靠性、臨床相關性和可操作性。主要資料來源包括對心臟外科、創傷科、腫瘤科和婦產科臨床負責人的深度訪談，以及與採購專家、生物醫學工程師和醫院高級管理人員的討論，以了解推動技術應用和阻礙技術應用的跨職能觀點。這些定性見解與二手文獻、臨床指南、監管文件和同行評審研究進行三角驗證，以檢驗臨床結論和技術性能。

透過對產品、治療方法、應用和最終用戶等維度進行結構化的細分映射，確保分析的嚴謹性，從而實現對技術適用性和採納標準的一致性比較。與臨床和供應鏈專家舉辦的檢驗研討會，有助於完善假設並考慮區域差異。透過將製造商的產品規格與實際使用模式進行匹配，並研究能夠說明實施挑戰和成功因素的用例，進一步增強了資料的完整性。

透過清晰記錄專家訪談、採用匿名化通訊協定以及建立可複現的技術和治療方法分類框架，確保了倫理考量和調查方法的透明度。最終形成的方法論嚴謹的綜合分析，兼顧了定性研究的深度和可交叉驗證的證據，為讀者提供了戰略決策的可靠依據，而無需依賴專有的市場數據。

一項結論性的綜合分析證實，整合臨床創新、採購靈活性和供應彈性對於在醫療保健環境中充分發揮患者血液管理的潛力至關重要。

患者血液管理不再是輔助性的臨床問題，而是手術全期卓越營運、供應鏈韌性和價值導向醫療的核心組成部分。自體輸血、凝血監測、止血劑和拋棄式的進步，使臨床醫生能夠減少對異體輸血的依賴，並根據患者的個別風險狀況制定個人化的干涉措施。同時，採購負責人和製造商必須應對關稅相關的壓力、供應鏈重組以及維持技術應用所需的有力臨床證據。

展望未來，藥品福利管理（PBM）的成功將取決於相關人員能否將臨床創新與切實可行的商業和營運策略結合。優先考慮術前最佳化、投資照護現場能力並建立多學科PBM計畫的醫院和專科中心將更有利於改善治療效果並應對資源限制。能夠根據不同的醫療環境調整產品設計、注重可靠的循證醫學證據並加強本地分銷管道的製造商和供應商將能夠獲得持續的需求並支持長期的臨床應用。

最終，對病人安全、結果透明度和穩健供應鏈的關注將決定藥品福利管理（PBM）創新成果能否有效轉化為日常臨床實踐。相關人員，將在品質、安全和設施準備方面看到可衡量的益處。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧演算法應用於預測手術期間個別患者的輸血需求
  • 引入照護現場血紅蛋白和血液凝固檢驗，以指導即時輸血決策並減少異體輸血的使用。
  • 引入自體血液回收和術中自體輸血技術，以最大限度地減少大型手術期間的輸血量
  • 監管和報銷獎勵推動了綜合性患者血液管理認證計畫的出現
  • 擴大產科和創傷科患者血液管理通訊協定，以控制出血並改善孕產婦結局
  • 在各種醫療環境中利用遠端醫療平台進行術前貧血評估和輸血後監測
  • 鐵缺乏症的篩檢和管理日益被認為是實證醫學的基礎組成部分。
  • 加強多學科團隊間的協作，以實施限制性輸血閾值和強化病患安全措施
  • 整合真實世界證據和衛生經濟學分析，以證明病患血液管理的成本節約和臨床效益。
  • 醫院正擴大採用由預測分析和決策支援系統支援的、針對特定患者的輸血演算法。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的患者血液管理市場

  • 抗纖溶藥物
  • 自體輸血系統
  • 血液成分分離系統
  • 血液管理耗材
    • 細胞清洗套件
    • 血液收集池
    • 過濾裝置
  • 凝血監測系統
    • 實驗室分析設備
    • 照護現場設備
  • 止血劑和密封劑
    • 密封系統
    • 局部止血劑
  • 膨鬆劑

9. 按治療類型分類的患者血液管理市場

  • 異體輸血
  • 自體輸血
  • 細胞拯救
  • 止血管理
    • 抗纖溶治療
    • 局部止血療法
  • 手術全期血液保護
    • 術中技術
    • 術後護理
    • 術前最佳化

第10章 病人血液管理市場：依應用分類

  • 心血管外科
    • 主動脈手術
    • 冠狀動脈繞道手術手術
    • 瓣膜置換手術
  • 擇期手術
  • 產科
  • 腫瘤治療
    • 化療
    • 放射線治療
  • 創傷

第11章 以最終用戶分類的病患血液管理市場

  • 門診手術中心
  • 診所
  • 醫院
  • 專業中心
    • 癌症治療中心
    • 心臟護理中心
    • 創傷中心

12. 按地區分類的患者血液管理市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 集團病患血液管理市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國患者血液管理市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Haemonetics Corporation
    • Fresenius Kabi AG
    • Grifols, SA
    • Terumo Corporation
    • Baxter International Inc.
    • Roche Diagnostics International AG
    • Octapharma AG
    • CSL Limited
    • ZOLL Medical Corporation
    • Macopharma SA
Product Code: MRR-0372549B1FF1

The Patient Blood Management Market is projected to grow by USD 32.22 billion at a CAGR of 8.23% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 17.10 billion
Estimated Year [2025] USD 18.50 billion
Forecast Year [2032] USD 32.22 billion
CAGR (%) 8.23%

An integrative introduction to patient blood management that frames clinical priorities, supply resilience, and technological enablers driving perioperative safety and institutional strategy

Patient blood management is evolving into a cross-disciplinary imperative that intersects perioperative care, transfusion medicine, supply chain stewardship, and value-driven clinical outcomes. The field prioritizes minimizing exposure to allogeneic blood, optimizing hemostasis, and aligning therapeutic interventions with patient-specific risk profiles. As hospitals and specialty centers navigate growing procedural complexity and heightened scrutiny over safety and costs, PBM practices are increasingly central to clinical governance and quality improvement agendas.

Clinicians, administrators, and supply chain leaders now view PBM through multiple lenses: clinical efficacy, procedural efficiency, and resilience against disruptions to blood availability. Advances in point-of-care coagulation monitoring and autologous technologies enable more precise intraoperative decision-making, while innovations in hemostats, sealants, and disposable systems support safer surgical pathways. These technological shifts are complemented by evolving clinical protocols that emphasize preoperative optimization and postoperative conservation, making PBM both a clinical and organizational priority.

Moreover, patient-centric care models are reframing how therapeutic choices are communicated and implemented. Shared decision-making around transfusion thresholds, alternatives such as cell salvage or antifibrinolytic therapy, and the integration of perioperative optimization protocols underscore a broader cultural shift in hospitals and specialty centers. In this context, PBM becomes an instrument for clinical excellence, operational resilience, and measurable improvements in patient outcomes.

A detailed analysis of the transformative clinical, technological, and operational shifts redefining patient blood management practices and procurement priorities across care settings

The landscape of blood management is being reshaped by multiple converging forces that redefine clinical pathways and procurement strategies. Technological maturation in autotransfusion systems and blood component separation devices enables safer reuse of autologous blood and reduces dependency on external supply, while next-generation coagulation monitoring systems and point-of-care diagnostics support faster, evidence-based intraoperative interventions. These advances increase the granularity of perioperative decision-making and elevate the role of real-time data in guiding transfusion practices.

Simultaneously, the development and wider adoption of hemostats, sealant systems, and topical agents have transformed how surgical bleeding is managed across specialties. Improved formulations and delivery mechanisms reduce surgical time and transfusion needs, and when combined with antifibrinolytic agents and volume expanders, they support more conservative transfusion strategies. This clinical evolution dovetails with operational trends toward bundled payments and value-based procurement, incentivizing hospitals to demonstrate outcomes-driven use of PBM tools.

Finally, the strategic shift toward decentralized care and growth of ambulatory surgical centers is prompting manufacturers and suppliers to adapt product design and service models for varied care settings. Point-of-care devices engineered for speed and portability, alongside disposable-focused solutions, are increasingly relevant as care migrates out of traditional inpatient environments. As a result, stakeholders must balance innovation adoption with training, interoperability, and long-term clinical evidence to fully realize the benefits of these transformative shifts.

An in-depth exploration of how recent tariff actions affect supply chain resilience, procurement strategy, manufacturing localization, and clinical adoption patterns across the patient blood management ecosystem

Changes in tariff policy can reverberate across the supply chain for medical devices and consumables, altering procurement calculus for hospitals, specialty centers, and distributors. When tariffs increase import costs for key components or finished devices, healthcare providers may encounter higher acquisition costs for autotransfusion systems, coagulation monitors, hemostats, and disposables. This shift compels supply chain leaders to reassess sourcing strategies, evaluate total cost of ownership, and prioritize suppliers with diversified manufacturing footprints or localized production capabilities.

Beyond immediate pricing effects, tariff-driven adjustments influence long-term supplier strategies. Manufacturers may accelerate localization of critical production, invest in regional manufacturing hubs, or modify product portfolios to reduce exposure to vulnerable supply corridors. Such moves can improve resilience over time but may require near-term capital expenditure that affects pricing dynamics. For providers, the consequence is a renewed emphasis on procurement agility: multi-supplier contracting, inventory optimization, and longer-term purchasing agreements with flexibility clauses become important tools to mitigate volatility.

Clinically, higher device or disposable costs could influence adoption curves for certain technologies unless providers can clearly link them to improved outcomes or operational efficiencies. Therefore, demonstrating clinical and economic value through robust evidence becomes essential to sustain adoption. Finally, regulatory oversight and customs compliance complexities introduced by new tariff regimes can increase administrative burden, encouraging healthcare organizations to invest in compliance capabilities and to partner more closely with suppliers to streamline cross-border logistics and maintain uninterrupted access to critical PBM products.

Comprehensive segmentation insights revealing how product classes, therapeutic approaches, clinical applications, and care settings interact to shape adoption pathways and commercialization strategies

Insightful segmentation illuminates where clinical need, technology fit, and purchasing behavior intersect, enabling targeted strategies across product, therapy, application, and end-user dimensions. Based on product type, the landscape includes antifibrinolytics, autotransfusion systems, blood component separation systems, blood management disposables, coagulation monitoring systems, hemostats and sealants, and volume expanders; within blood management disposables the focus extends to cell washing kits, collection reservoirs, and filtration devices, while coagulation monitoring is distinguished by laboratory analyzers and point-of-care devices and hemostats and sealants break down into sealant systems and topical hemostats. Each product category follows its own adoption arc, driven by clinical evidence, ease of use, consumable economics, and integration with perioperative workflows.

Considering therapy type, the framework spans allogeneic transfusion, autologous transfusion, cell salvage, hemostasis management, and perioperative blood conservation; the hemostasis management domain further divides into antifibrinolytic therapy and topical hemostats therapy, and perioperative blood conservation encompasses intraoperative techniques, postoperative care, and preoperative optimization. Therapy-focused segmentation reveals where clinical protocols and multidisciplinary teams can most effectively reduce transfusion exposure and improve outcomes, with perioperative optimization often serving as the nexus between preoperative assessment and intraoperative technology utilization.

Application-based segmentation highlights cardiovascular surgery, elective surgery, obstetrics, oncology treatments, and trauma; within cardiovascular surgery the clinical complexity varies across aortic surgery, coronary artery bypass grafting, and valve replacement procedures, while oncology treatments are differentiated by chemotherapy and radiotherapy contexts. These clinical settings dictate distinct PBM priorities: elective surgery programs often emphasize preoperative optimization and intraoperative hemostatic control, trauma care stresses rapid access to point-of-care coagulation data and blood component separation, and oncology care requires coordinated strategies to manage bleeding risk during complex treatment regimens.

From an end-user perspective, adoption patterns span ambulatory surgical centers, clinics, hospitals, and specialty centers; specialty centers are further categorized into cancer treatment centers, cardiac care centers, and trauma centers. Each care setting imposes different requirements for device footprint, training intensity, consumable logistics, and reimbursement sensitivity. Ambulatory environments prioritize compact, easy-to-use devices with streamlined disposables, whereas tertiary hospitals and specialty centers demand scalable systems that can integrate with intensive care workflows and support high-volume, high-acuity cases. Understanding these segmentation dynamics is essential for product positioning, evidence generation, and tailored commercial strategies that resonate with clinicians and procurement stakeholders alike.

A strategic examination of how regional healthcare structures, reimbursement models, and regulatory environments in the Americas, Europe Middle East & Africa, and Asia-Pacific drive differentiated patient blood management adoption

Regional dynamics influence clinical practice patterns, procurement preferences, and regulatory navigation, producing distinct pathways to adoption across major geographies. In the Americas, healthcare systems vary from large integrated hospital networks to a proliferation of ambulatory surgical centers, creating demand for both high-end integrated systems and portable point-of-care solutions; reimbursement paradigms and private payer influences also accelerate adoption of evidence-backed PBM interventions in settings where cost-effectiveness data can be translated directly into procurement decisions.

In Europe, Middle East & Africa, a diverse regulatory and reimbursement landscape leads to differentiated adoption curves. Western European health systems with centralized procurement and strong emphasis on clinical guidelines often favor technologies backed by robust clinical data and long-term outcome studies, while emerging markets in the region are driven by affordability, modular solutions, and partnerships that enable local training and supply resilience. Regulatory harmonization efforts and regional procurement initiatives can both enable and constrain market entry depending on compliance alignment and certification pathways.

Across Asia-Pacific, rapid expansion of procedural volumes and ongoing investments in hospital infrastructure create opportunities for accelerated adoption of PBM technologies. Variations in healthcare financing and provider capabilities shape demand for scalable devices, consumable-efficient disposables, and cost-effective hemostatic solutions. In many markets across the region, localization of manufacturing and strategic partnerships with domestic distributors optimize cost structures and facilitate faster implementation, particularly in tertiary and specialty centers that are expanding surgical and oncology services. Overall, regional strategies must reconcile local regulatory requirements, healthcare financing models, and provider practice patterns to succeed.

An authoritative overview of how global manufacturers, niche innovators, and regional suppliers compete through clinical evidence, supply resilience, and partnership-driven commercialization in blood management

The competitive landscape is composed of diversified global manufacturers, specialized device innovators, and nimble regional suppliers, each pursuing strategies that emphasize clinical evidence, service delivery, and supply resilience. Established device companies leverage broad product portfolios to offer integrated solutions that bundle autotransfusion systems, coagulation monitoring platforms, and disposables, while smaller innovators often target specific clinical pain points with focused technologies such as advanced sealants, single-use filtration systems, or rapid point-of-care analyzers.

Strategic behaviors among companies include investment in clinical evidence generation, expansion of distribution channels, and collaborative arrangements with clinical centers to pilot new technologies. Partnerships with hospitals and specialty centers for real-world evidence collection strengthen value propositions and facilitate guideline inclusion. Meanwhile, supply chain integration and manufacturing diversification are important differentiators, with companies seeking regional production sites or multi-sourcing models to limit exposure to trade disruptions and tariff shifts.

Mergers, acquisitions, and licensing arrangements continue to shape capability portfolios, enabling companies to complement device offerings with consumables and services that drive recurring revenue streams. At the same time, corporate emphasis on training, remote servicing, and digital tools enhances product adoption and long-term customer retention. For purchasers and partners, the critical lens is alignment between clinical utility, total cost of ownership, and vendor commitments to evidence, support, and supply continuity.

Actionable recommendations for executives and clinical leaders to align evidence generation, supply diversification, pricing flexibility, and tailored adoption strategies for durable patient blood management success

Industry leaders should prioritize a coordinated approach that aligns clinical evidence generation with adaptive supply chain strategies and commercial models tailored to distinct care settings. Investing in rigorous clinical studies that demonstrate improvements in outcomes and procedural efficiency will help justify adoption of devices and therapies even in environments with constrained budgets. Equally important is the creation of flexible pricing and contracting options that reflect total cost of ownership and enable hospitals to trial technologies with limited upfront commitment.

Operationally, companies and provider networks should accelerate efforts to diversify manufacturing and distribution to mitigate tariff and logistics risks. Localization of production or strategic partnerships with regional manufacturers can lower exposure to cross-border disruptions and create cost advantages in competitive procurement processes. In parallel, building comprehensive training programs and remote-support ecosystems ensures that new technologies are implemented safely and effectively, driving clinician confidence and sustainable utilization.

Finally, aligning product development with end-user realities is paramount. Devices and disposables designed for ease of use in ambulatory and clinic environments will expand addressable markets, while modular systems that can scale for tertiary hospitals will meet demands of specialty centers. Cross-functional collaboration between clinical teams, procurement, and supplier account management will accelerate integration of PBM practices into standard care pathways and secure long-term value realization.

A transparent and rigorous research methodology combining expert interviews, clinical guideline synthesis, segmentation mapping, and validation workshops to underpin strategic insights without relying on proprietary market quantification

The research approach integrates multiple data streams and expert validation to ensure findings are robust, clinically relevant, and operationally actionable. Primary inputs include in-depth interviews with clinical leaders across cardiac surgery, trauma, oncology, and obstetrics, as well as discussions with procurement specialists, biomedical engineers, and senior hospital administrators to capture cross-functional perspectives on adoption drivers and barriers. These qualitative insights are triangulated with secondary literature, clinical guidelines, regulatory documents, and peer-reviewed studies to validate clinical assertions and technology performance.

Analytical rigor is maintained through structured segmentation mapping across product, therapy, application, and end-user dimensions, enabling consistent comparison of technology fit and adoption criteria. Validation workshops with clinical experts and supply chain professionals help refine assumptions and contextualize regional nuances. Data integrity is further strengthened by reconciling manufacturer product specifications with real-world usage patterns and by reviewing case studies that illustrate implementation challenges and success factors.

Ethical considerations and methodological transparency are upheld through clear documentation of inclusion criteria for expert interviews, anonymization protocols, and a replicable framework for categorizing technologies and therapies. The result is a methodologically sound synthesis that balances qualitative depth with cross-referenced evidence, equipping readers with a defensible basis for strategic decisions without relying on proprietary market quantifications.

A conclusive synthesis affirming that integrating clinical innovation, procurement agility, and supply resilience is essential to realize the full potential of patient blood management across care environments

Synthesis of the preceding insights underscores a clear strategic imperative: patient blood management is no longer an ancillary clinical concern but a core component of perioperative excellence, supply chain resilience, and value-based care. Advancements in autotransfusion, coagulation monitoring, hemostatic agents, and disposables are enabling clinicians to reduce reliance on allogeneic transfusion and to tailor interventions to individual patient risk profiles. At the same time, procurement leaders and manufacturers must navigate tariff-related pressures, supply chain realignment, and the need for compelling clinical evidence to sustain adoption.

Looking ahead, success in PBM will hinge on the ability of stakeholders to integrate clinical innovation with pragmatic commercial and operational strategies. Hospitals and specialty centers that prioritize preoperative optimization, invest in point-of-care capabilities, and foster multidisciplinary PBM programs will be better positioned to improve outcomes and manage resource constraints. Manufacturers and suppliers that align product design with diverse care settings, commit to robust evidence generation, and strengthen regional supply channels will capture enduring demand and support long-term clinical adoption.

Ultimately, the collective focus on patient safety, outcome transparency, and resilient supply chains will determine how effectively PBM innovations translate into routine clinical practice. Stakeholders that act decisively to bridge clinical priorities with procurement flexibility and operational preparedness will create measurable advantages in quality, safety, and institutional readiness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms in predicting individual patient transfusion requirements during surgery
  • 5.2. Adoption of point-of-care hemoglobin and coagulation testing to guide real-time transfusion decisions and reduce allogeneic blood use
  • 5.3. Implementation of cell salvage and intraoperative autotransfusion techniques to minimize donor blood transfusion in major surgeries
  • 5.4. Emergence of comprehensive patient blood management accreditation programs driven by regulatory and reimbursement incentives
  • 5.5. Expansion of patient blood management protocols in obstetrics and trauma to address hemorrhage management and improve maternal outcomes
  • 5.6. Utilization of telehealth platforms for preoperative anemia assessment and post-transfusion monitoring in diverse healthcare settings
  • 5.7. Growing emphasis on iron deficiency screening and management as a foundational component of evidence-based patient blood management
  • 5.8. Increasing collaboration between multidisciplinary teams to implement restrictive transfusion thresholds and enhanced patient safety measures
  • 5.9. Integration of real-world evidence and health economics analyses to demonstrate cost savings and clinical benefits of patient blood management
  • 5.10. Rising adoption of patient-tailored transfusion algorithms supported by predictive analytics and decision support systems in hospitals

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Patient Blood Management Market, by Product Type

  • 8.1. Antifibrinolytics
  • 8.2. Autotransfusion Systems
  • 8.3. Blood Component Separation Systems
  • 8.4. Blood Management Disposables
    • 8.4.1. Cell Washing Kits
    • 8.4.2. Collection Reservoirs
    • 8.4.3. Filtration Devices
  • 8.5. Coagulation Monitoring Systems
    • 8.5.1. Laboratory Analyzers
    • 8.5.2. Point Of Care Devices
  • 8.6. Hemostats And Sealants
    • 8.6.1. Sealant Systems
    • 8.6.2. Topical Hemostats
  • 8.7. Volume Expanders

9. Patient Blood Management Market, by Therapy Type

  • 9.1. Allogeneic Transfusion
  • 9.2. Autologous Transfusion
  • 9.3. Cell Salvage
  • 9.4. Hemostasis Management
    • 9.4.1. Antifibrinolytic Therapy
    • 9.4.2. Topical Hemostats Therapy
  • 9.5. Perioperative Blood Conservation
    • 9.5.1. Intraoperative Techniques
    • 9.5.2. Postoperative Care
    • 9.5.3. Preoperative Optimization

10. Patient Blood Management Market, by Application

  • 10.1. Cardiovascular Surgery
    • 10.1.1. Aortic Surgery
    • 10.1.2. Coronary Artery Bypass Grafting
    • 10.1.3. Valve Replacement Procedures
  • 10.2. Elective Surgery
  • 10.3. Obstetrics
  • 10.4. Oncology Treatments
    • 10.4.1. Chemotherapy
    • 10.4.2. Radiotherapy
  • 10.5. Trauma

11. Patient Blood Management Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Specialty Centers
    • 11.4.1. Cancer Treatment Centers
    • 11.4.2. Cardiac Care Centers
    • 11.4.3. Trauma Centers

12. Patient Blood Management Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Patient Blood Management Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Patient Blood Management Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Haemonetics Corporation
    • 15.3.2. Fresenius Kabi AG
    • 15.3.3. Grifols, S.A.
    • 15.3.4. Terumo Corporation
    • 15.3.5. Baxter International Inc.
    • 15.3.6. Roche Diagnostics International AG
    • 15.3.7. Octapharma AG
    • 15.3.8. CSL Limited
    • 15.3.9. ZOLL Medical Corporation
    • 15.3.10. Macopharma SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PATIENT BLOOD MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PATIENT BLOOD MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PATIENT BLOOD MANAGEMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS PATIENT